

April 26, 2018
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

**(Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of
Stock Acquisition Rights (Stock Option) to the Company's Directors**

Symbio Pharmaceuticals Limited (“the Company”) today announced a correction to its press release issued on April 26, 2018, entitled "Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors." In the press release, the payment amount for the stock options was misstated. The corrections are as follows, with the misstated and revised information shown in underline:

<Misstated information>

1. Amount to be paid for stock options and calculation method

(1) Amount to be paid per one stock option : 20,300 yen

(2) Amount to be paid per one share : 203 yen

The person who receives the allotment of stock acquisition rights shall set off his/her claims for compensation against the Company in lieu of payment of monies for the stock acquisition rights allotted.

<Corrected information>

1. Amount to be paid for stock options and calculation method

(1) Amount to be paid per one stock option : 19,800 yen

(2) Amount to be paid per one share : 198 yen

The person who receives the allotment of stock acquisition rights shall set off his/her claims for compensation against the Company in lieu of payment of monies for the stock acquisition rights allotted.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125